You are here

  • Home
  • Archive
  • Volume 93, Issue Suppl 2
  • Lb1.7 Australian national surveillance of juvenile onset recurrent respiratory papillomatosis: declining incidence post quadrivalent hpv vaccination

Article Text

Article menu

Download PDFPDF

LB1 – Late Breakers Oral Sesssion
Lb1.7 Australian national surveillance of juvenile onset recurrent respiratory papillomatosis: declining incidence post quadrivalent hpv vaccination
Free
  1. Novakovic1,
  2. J Brotherton2,
  3. Suzanne Garland3,
  4. A Cheng4,
  5. R Booy5,
  6. P Walker6,
  7. R Berkowitz7,
  8. H Harrison8,
  9. R Black9,
  10. C Perry9,
  11. S Vijayasekaran10,
  12. D Wabnitz11,
  13. Tabrizi Sn12,
  14. Cornall Am12,
  15. E Elliott13,
  16. Y Zurynski13
  1. 1University of Sydney Medical School, University of Sydney, Sydney, Australia
  2. 2National HPV Vaccination Program Register, VCS, East Melbourne, Australia
  3. 3Royal Women’s Hospital, Department of Microbiology and Infectious Diseases, Parkville, Australia
  4. 4Children’s Hospital Westmead, Sydney, Australia
  5. 5National Centre For Immunisation Research And Surveillance, Children’s Hospital Westmead, Sydney, Australia
  6. 6John Hunter Hospital, Newcastle, Australia
  7. 7Royal Children’s Hospital, Parkville, Australia
  8. 8Prince of Wales Children’s Hospital, Randwick, Australia
  9. 9Lady Cilento Children’s Hospital, Brisbane, Australia
  10. 10Princess Margaret Hospital For Children, Perth, Australia
  11. 11Women’s And Children Hospital, Adelaide, Australia
  12. 12Royal Women’s Hospital, Department of Microbiology And Infectious Diseases, And Murdoch, Parkville, Australia
  13. 13Australian Paedatric Surveillance Unit, Children’s Hospital Westmead, Sydney, Australia

Abstract

Introduction To estimate and monitor national incidence of Juvenile onset Recurrent Respiratory Papillomatosis (JoRRP) in Australia following the extensive quadrivalent HPV vaccine catch up program (females aged 12–26 years in 2007–2009, which included women of child bearing age) and to assess demographics and risk factors of incident cases.

Methods The Australian Paediatric Surveillance Unit (APSU) undertakes surveillance of rare paediatric diseases by contacting practitioners monthly to report cases. We utilised this well established methodology to undertake prospective population based surveillance of JoRRP by enrolment in APSU of paediatric ENT surgeons, designing a JoRRP case reporting form, and offering clinicians HPV typing of incident cases. Surveillance commenced Oct 2011 and we report here findings for the five-year period to end 2016.

Results Using Australian Bureau of Statistics population estimates for children 0–15 years, the average annual incidence rate over the period was 0.12 per 1 00 000. The largest number of cases was reported in the first year, with a decreasing frequency each year thereafter. The rate declined from 0.3 per 1 00 000 in 2012 to 0.04 per 1 00 000 in 2016. Among incident cases, no mothers had been vaccinated prior to pregnancy, 20% had a past history of genital warts, 60% of cases were male, and 60% were first born. The majority were born by vaginal delivery. Four incident cases were genotyped; all were positive for HPV6 (n=1) or HPV11 (n=3).

Conclusion To our knowledge this is the first report internationally documenting a decline in JoRRP incidence in a population of children following the introduction of a quadrivalent HPV vaccination program.

Support: I Professor Suzanne Garland, have received Grants to my institution from Commonwealth Department of Health for HPV genoprevalance surveillance post vaccination, Merck and GSK (GlaxoSmithKline) to perform phase 3 clinical vaccine trials: Merck to evaluate HPV in RRP post vaccination programme, CSL for HPV in cervical cancer study, and VCA (Victoria Cancer Agency) for a study on effectiveness of public health HPV vaccine study plus a study on associations of early onset cancers. I have received speaking fees from MSD and SPMSD for work performed in my personal time. Merck paid for travel and accommodation to present at HPV Advisory board meetings.

https://doi.org/10.1136/sextrans-2017-053264.108

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.